title: Accelerated immunodeficiency by anti-CCR5 treatment in HIV infection.
abstract: In 50% of progressing HIV-1 patients, CXCR4-tropic (X4) virus emerges late in infection, often overtaking CCR5-tropic (R5) virus as the dominant viral strain. This "phenotypic switch" is strongly associated with rapidly declining CD4(+) T cell counts and AIDS onset, yet its causes remain unknown. Here, we analyze a mathematical model for the mechanism of X4 emergence in late-stage HIV infection and use this analysis to evaluate the utility of a promising new class of antiretroviral drugs -- CCR5 inhibitors -- in dual R5, X4 infection. The model shows that the R5-to-X4 switch occurs as CD4(+) T cell activation levels increase above a threshold and as CD4(+) T cell counts decrease below a threshold during late-stage HIV infection. Importantly, the model also shows that highly active antiretroviral therapy (HAART) can inhibit X4 emergence but that monotherapy with CCR5 blockers can accelerate X4 onset and immunodeficiency if X4 infection of memory CD4(+) T cells occurs at a high rate. Fortunately, when CXCR4 blockers or HAART are used in conjunction with CCR5 blockers, this risk of accelerated immunodeficiency is eliminated. The results suggest that CCR5 blockers will be more effective when used in combination with CXCR4 blockers and caution against CCR5 blockers in the absence of an effective HAART regimen or during HAART failure.
authors.affiliation: Biophysics Graduate Group, University of California, Berkeley, CA, USA. arielw@berkeley.edu
authors.forename: Ariel D
authors.initials: AD
authors.lastname: Weinberger
authors.forename: Alan S
authors.initials: AS
authors.lastname: Perelson
authors.forename: Ruy M
authors.initials: RM
authors.lastname: Ribeiro
authors.forename: Leor S
authors.initials: LS
authors.lastname: Weinberger
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000009:adverse effects*; D065100:CCR5 Receptor Antagonists; D015497:HIV-1 / Q000145:classification / Q000472:pathogenicity; D006801:Humans; D008954:Models, Biological; D019713:Receptors, CCR5 / Q000378:metabolism; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors / Q000378:metabolism; D014774:Virulence / Q000187:drug effects*
chemical_list: D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; C527276:CXCR4 protein, human; D019713:Receptors, CCR5; D019718:Receptors, CXCR4
references.citation: J Immunol. 2002 Aug 1;169(3):1159-67
references.pmid: 12133935
references.citation: Nature. 1995 Jan 12;373(6510):123-6
references.pmid: 7816094
references.citation: J Virol. 2000 Jun;74(11):5016-23
references.pmid: 10799575
references.citation: Blood. 2000 Jan 1;95(1):249-55
references.pmid: 10607709
references.citation: Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5640-5
references.pmid: 15064398
references.citation: Annu Rev Immunol. 1999;17:657-700
references.pmid: 10358771
references.citation: J Virol. 2006 Jan;80(2):854-65
references.pmid: 16378987
references.citation: J Exp Med. 1994 Sep 1;180(3):1159-64
references.pmid: 8064232
references.citation: J Clin Invest. 2001 Feb;107(4):431-8
references.pmid: 11181642
references.citation: AIDS. 2003 Sep 5;17(13):1881-8
references.pmid: 12960820
references.citation: J Virol. 2006 Jan;80(2):802-9
references.pmid: 16378982
references.citation: J Virol. 2000 Aug;74(15):7005-15
references.pmid: 10888639
references.citation: Virology. 2004 Oct 10;328(1):19-29
references.pmid: 15380354
references.citation: J Exp Med. 2005 Oct 17;202(8):1087-98
references.pmid: 16230476
references.citation: J Exp Med. 2001 Nov 5;194(9):1277-87
references.pmid: 11696593
references.citation: AIDS Res Hum Retroviruses. 2004 Jan;20(1):111-26
references.pmid: 15000703
references.citation: J Exp Med. 1998 Dec 7;188(11):2057-65
references.pmid: 9841919
references.citation: J Virol. 1995 Mar;69(3):1810-8
references.pmid: 7853521
references.citation: Annu Rev Immunol. 1999;17:625-56
references.pmid: 10358770
references.citation: Int Immunol. 1995 Sep;7(9):1417-24
references.pmid: 7495749
references.citation: Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5215-20
references.pmid: 10220446
references.citation: Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10977-82
references.pmid: 12963814
references.citation: Nature. 1995 Jan 12;373(6510):117-22
references.pmid: 7529365
references.citation: AIDS. 2002 Mar 8;16(4):597-603
references.pmid: 11873003
references.citation: J Exp Med. 1998 Apr 20;187(8):1295-303
references.pmid: 9547340
references.citation: Proc Natl Acad Sci U S A. 2005 May 31;102(22):8000-5
references.pmid: 15911767
references.citation: J Infect Dis. 2002 Oct 1;186(7):914-21
references.pmid: 12232831
references.citation: N Engl J Med. 2008 Oct 2;359(14):1429-41
references.pmid: 18832244
references.citation: J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):267-75
references.pmid: 16249699
references.citation: Bull Math Biol. 2007 Oct;69(7):2361-85
references.pmid: 17554585
references.citation: Nat Med. 2005 Nov;11(11):1170-2
references.pmid: 16205738
references.citation: Annu Rev Immunol. 2003;21:265-304
references.pmid: 12524385
references.citation: J Infect Dis. 2008 Jan 15;197(2):262-5
references.pmid: 18179388
references.citation: J Virol. 2006 May;80(10):4909-20
references.pmid: 16641282
references.citation: Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15590-5
references.pmid: 12434015
references.citation: J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):530-6
references.pmid: 16044003
references.citation: PLoS Biol. 2005 Nov;3(11):e378
references.pmid: 16248677
references.citation: Nature. 2005 Apr 28;434(7037):1148-52
references.pmid: 15793562